

CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
https://cajmns.centralasianstudies.org/index.php/CAJMNS
Volume: 05 Issue: 02 | April 2024 ISSN: 2660-4159

.

Article

The Role of the Vosoritide Drug in Childrens with Achondroplasia

Ahmed Tawfeeq Ahmed[1*], Inas Hazim Hameed , Nibras Hazim Hameed[3]

1. Ministry of Education, Tikrit, Iraq
2. University of Tikrit, College of Sciences
3. University of Tikrit, College of Sciences

* Correspondence: enshazim@uomustansiriyah.edu.iq

Abstract: Achondroplasia is a hereditary disorder that follows an autosomal dominant inheritance pattern. The condition is a result of harmful mutations in the FGFR3 gene, which occur when there are two different versions of the gene presentMutations in the de novo gene FGFR3 prevent the development of chondrocytes forward unregulated growth and instead promote the growth of existing bone,this negatively affects the creation of new bone. Vosoritide, additionally called voxzogo, represents a significant leap approaching the approval of a pharmaceutical treatment that is specifically intended to address achondroplasia. Aforementioned medication has been approved for use in-home injections, these injections must be conducted under the supervision of a knowledgeable nurse in ordering to ensure proper guidance and safety.

Keywords: Achondroplasia;Vosoritide;Metabolism;Dosage.

1. Introduction

Achondroplasia is the uttermost common structure of dwarfism.The FGFR3 gene is responsible for detrimental heterozygous mutations. This variation disrupts the process of endochondral ossification and has enduring consequences. Achondroplasia is the most commonly divulged skeletal abnormality, it affects around 1 out of every 20,000 newborns (Zikeli, 2022). Common physical symptoms of achondroplasia include dwarfism, shortened limbs, midfacial recirculation, and forward heading; these are all associated with macrocephaly, diminutive fingers, and hands that are trident-shaped. Additionally, they include an increased degree of mobility in the joints[2].

Frequently, recounted effects encompass the blocking of the foramen magnum, slowing of the motor milestones, recurring infections in the ear, hearing issues, sleep apnea, overcrowding of teeth, and the blocking of the spine[3]. Pain, which is typically felt in the lower limbs, joints, and spinal region, is common during observation. Additionally, it's important to recognize that children of older age that have a lower energy level and are overweight or obese will have a higher weight as well (Savarirayan, 2021). These diseases have a important impingement on a child's development, socialization and emotional maturity, this will affect their participation in school activities.following the same rules as their peers, and taking care of themselves[4–8]. Receivable to these obstacles, a large portion of young people need assistance or special technologies in order to complete everyday tasks, which often has negative societal and sentimental effects (Qi,

Citation: Ahmed, A. T. the Role of the Vesoritide Drug in Childrens with Achondroplasia. Central Asian Journal of Medical and Natural Science 2024, 5(4), 835-840-666.

Received: 10th June 2024
Revised: 11th July 2024
Accepted: 24th August 2024
Published: 28th Sept 2024

2024). Afterwards getting a diagnosis of achondroplasia, a child may harbor a sense of self-hatred towards their physical characteristics, they may also transform into adversaries because of the involuntary focus they are receiving, social disdain, or the example of swaggering[2]. Also, they may believe that life is more challenging for them in a more extensive eccentricity[3]. Children and Parents have animpressive capacity to adapt to difficult situations, and many of them have increased levels of sympathy and comprehension towards the people who receive effective rival support[5].

Acquired proficiency in gross motor skills

Infants with achondroplasia include a tendency to have a later onset of their gross motor abilities than other youngsters. To maintain stability, more power in the back and neck extensor muscles is required in order to support a disproportionately big head on a small and very flexible neck (Tofts, 2024). This often leads to a delay in achieving control over head movements. Due to the hypotonicity commonly observed in babies with achondroplasia, the process of establishing strength and control tends to be significantly prolonged. The present therapy for spinal deformities considerably postpones the ability to sit independently and erect, as well as hinders the progress of gross motor skills. Young children with achondroplasia often employ unconventional methods of autonomous movement due to their shorter limbs, deviating from the typical developmental trajectory (Taylor-Miller, 2024). Children with achondroplasia seldom engage in foot play due to the limitations imposed by their shortened limbs [9]. Considered to fall within the normal range for children in this age group:

- By five months, the patient is able to raise their head when lying down.
- Capable of rolling after seven months.
- Beginning at the age of 16 months, beginning a full-time career.
- Sitting alone by 17 months.
- 19-month-olds are capable of walking with a hand.
- At 20 months, be able to walk on your own.
- By 23 months, a child is capable of walking on their own.[9].

Vosoritide is the beginning medication approved by the FDA for treating achondroplasia. It may be simple to administer on a daily basis by a knowledgeable caregiver in the patient's home[10].

VOXZOGO is additionally known as vosoritide, and it is authorized by every U.S. Food and Drug Administration (FDA) to serve as a treatment for young patients with open epiphyses and achondroplasia. This drug is intentional to promote consecutive growth in children afflicted by it, and it's an alternative to class C natriuretic peptides[11].

2. Materials and Methods

The technique of action

Vosoritide is also known as voxzogo in particular situations, it's administered by daily subcutaneous injections. This medication interreact with signal-regulated kinases 1 and 2 (SRK1/2) in the mitogen-activated protein kinase pathway, this is facilitated by the natriuretic peptide receptor-B (NPR-B). This interaction ultimately leads to an increase in the reproduction and specialization of chondrocytes by blocking the transmission of signals to FGFR3 (see figure 1))[11].

3. Results



Figure 1: The technique by which the drug works in Vosoritide.

The beginning step III trial was a 52-week experimentation that was split up among multiple institutions. This research was a randomised study that lacked a containment group, this is ofttimes called a "placebo" group. The results demonstrated that vosoritide increased the average annual growth rate by 1.57 cm (between 1.22 and 1.93 cm) compared to the control group.A 2-year, open-label, phase 3 study that examined the growth rate of individuals who were treated with vosoritide, the average growth rate of these individuals increased From 5.39 cm/ year at 52 weeks to 5.52 cm/ year at 104 weeks. Similarly, populations that were formerly untreated and received vosoritide treatment increased from a typical annual growth of 3.81 cm to 5.43 cm.[13].

Negative effects and toxins

The uttermost commonplace adverse effects that were reported were injection site reactions and temporary low blood pressure, These adverse effects can be averted by consuming and drinking 8-12 ounces of fluids. Other common adverse reactions that were commonplace were arthralgia, lightheadedness, fatigue, and intestinal symptoms like vomiting, diarrhea, and enteritis.[11] The pain and discomfort associated with injections is uncomfortable and causes uneasiness[13].

Dosage and Method of Administration

It's suggested that a medicating specialist that specializes in the treatment of growth issues or skeletal issues should begin and lead the supervision of Voxzogotherapy[13].

Dosage

Beginning early intervention is essential in achieving the goals of children. The volume of Voxzogo is calculated by communicative into account the patient's weight and the concentration of vosoritide, as listed in (Table 1). The normal practice is to give 15 micrograms of weight per kilogram of body (Saitou, 2024). The suggested dosage is based on practical considerations that take into account different weights[13].

Overdose

laboratory research was conducted to determine the optimal concentrations of Voxzogo for a everyday dosage of up to 30 grams/day. Two patients collective in dosages that were higher than the recommended daily weight of 15 kilograms for a duration of five weeks. No adverse effects or symptoms were present when the dosage was increased past what was expected[13].

Table 1: shows the single dose volume in relation to the body's weight.

Body weight (kg)	***Voxzogo 0.4 miligrams Injecting fluid: 0.5 ml concentration: 0.8mg/ml***	***Voxzogo 0.56 miligrammes Diluent (water intended for injections): 0.7 ml concentration: 0.8mg/ml***	***Voxzogo 1.2 mg Diluent (water intended for injections): 0.6 ml concentration: 2 mg/ml***
Daily injection volume (ml)			
10 - 11	*0.30 ml*		
12-16		*0.35 ml*	
17 - 21		*0.40 ml*	
22 - 32		*0.50 ml*	
33-43			*0.25 ml*
44-59			*0.30 ml*
60-89			*0.35 ml*
≥ 90			*0.40 ml*

Metabolism

Vosoritide is anticipated to be metabolized via catabolic pathways, resulting in the breakdown of the compound into amino acids and tiny peptide fragments[13].

The nature of the container and its contents

0.4 mg of vosoritide powder and a mixture of soluble chemicals that can be ingested.

Powder:

A 2 mil bottle with a bromobutyl rubber cap and a white tab-top lid that is 2 inches tall.

Diluent:

Every syringe is made of glass and include been permeated with 0.5 ml of water for use in injections. It's imbibed with a bromobutyl turbine, and has a luer skullcap and a manipulator associated with it.

- The injection contains 0.56 mg of powdered vosoritide in addition to a mixture.

Powder:

The glass flask has a capacity of 2 ml and is equipped with a pink flap that closes, a bromobutyl rubber stopper and a pin.

Diluent:

The syringe is composed of glass and has a capacity for 0. 7 ml will be ingested and metabolized by the body.This, facilitated by the following specifications of the device: bromobutylimpelers that include a tamper-able seal and a luer-like tip skullcap.

•1.2 milligrams of vosoritide in powdered form, to be mixed with injectable diluents.

Powder:

The flask is composed of glass and has a rubber stopper that is made of bromobutyl. Additionally, it possesses a gray cap that flips over. The bottle has a capacity of 2 ml.

Diluent:

The syringe is composed of glass and include been brimming with 0.6 ml of water that is intended for injection. It's endowed with bromobutyl paddle arms and possesses a tamper-present seal (Savarirayan, 2024). The distal portion of the syringe's shaft contains a luermechanism[13].

Voxzogo should only be administered in the subcutaneous layer, which is the fatty layer that underlies the skin:

- Resist the effort of administering medication or fluids in clothing.
- Avoid identical sites of injection on consecutive occasions.
- Avoid injecting into pained, broken, red, delicate, or damaged skin.

The ensuing injection sites are recommended:

- The posterior aspect of the upper limbs.
- Limbs.

The measurement of the abdomen is 5 cm at the belly button.

- Gluteus maximus muscles [13], as attested in (Figure 2).



Figure 2: Optimal sites for injection.

4. Conclusion

- Ever Foramen Magnum Score for Achondroplasia has a high level of agreement across both individual observers and different observers (ICC=0.72), which is similar to the agreement shown in other scoring systems often employed in clinical settings. Prospective validation of the score using clinical findings is essential.
- Every physical exam of these children should include a evaluation of internal rotation of the tibia and/or bowing, and a referral to an orthopedic specialist is necessary if problems are encountered.
- The criteria for surgery in these children are often ambiguous, but they may involve misaligned bones, changes in walking (lateral push), or the development of pain in the knee or leg.
- Hemiepiphysiodesis, along with tibial-fibular osteotomies, is a successful treatment for individuals with symptomatic and progressive limb abnormalities.

REFERENCES

1. Aldhouse NVJ, Kitchen H, Johnson C, et al. Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials. Orphanet J Rare Dis. 2022;17(1):182.
2. Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and exposureresponse of vosoritide in children with achondroplasia. ClinPharmacokinet. 2022;61(2):263-280.
3. European Medicines Agency. Voxzogo 2022 [updated 2022 February]. https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo. Accessed 13 Mar 2023.
4. Ireland P. O'Donaghey S. Development of Australian children with achondroplasia. Journal of Developmental and BehaviouralPaediatrics. 2007; 31(1): 41-7.
5. Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146: 115872.

6. Lorne H, Newman CJ, Unger S. Is height important for quality of life in children with skeletal dysplasias? Eur J Med Genet. 2020;63(4): 103816.
7. McGraw SA, Henne JC, Nutter J, Larkin AA, Chen E. Treatment goals for achondroplasia: a qualitative study with parents and adults. AdvTher. 2022;39(7):3378–91.
8. Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1.
9. Pfeiffer KM, Brod M, Smith A, et al. Assessing physical symptoms, daily functioning, and wellbeing in children with achondroplasia. Am J Med Genet A. 2021;185(1):33–45.
10. Pfeiffer KM, Brod M, Smith A, Viuff D, Ota S, Charlton RW. Functioning and well-being in older children and adolescents with achondroplasia: a qualitative study. Am J Med Genet A. 2022;188(2): 454–62.
11. Qi, Y. (2024). Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model. *Clinical Pharmacokinetics*, *63*(5), 707–719. https://doi.org/10.1007/s40262-024-01371-6
12. Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growthpromoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23(12):2443-2447.
13. Saitou, H. (2024). Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data. *American Journal of Medical Genetics, Part A*, *194*(8). https://doi.org/10.1002/ajmg.a.63612
14. Savarirayan, R. (2021). Vosoritide treatment accelerates bone growth in children with achondroplasia. *Future Rare Diseases*, *1*(3). https://doi.org/10.2217/frd-2021-0009
15. Savarirayan, R. (2024). New treatments for children with achondroplasia. *The Lancet Child and Adolescent Health*, *8*(4), 301–310. https://doi.org/10.1016/S2352-4642(23)00310-3
16. Shediac R, Moshkovich O, Gerould H, et al. Experiences of children and adolescents living with achondroplasia and their caregivers. Mol Genet Genomic Med. 2022;10(4):e1891.
17. Taylor-Miller, T. (2024). Progress in managing children with achondroplasia. *Expert Review of Endocrinology and Metabolism*. https://doi.org/10.1080/17446651.2024.2390416
18. Tofts, L. (2024). Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia. *Children*, *11*(7). https://doi.org/10.3390/children11070789
19. U.S. Food and Drug Administration. Highlights of prescribing information. VOXZOGO (vosoritide) for injection, for subcutaneous use. Accessed August 8, 2022.
20. Zikeli, S. (2022). Achondroplasia in children: Vosoritide as the first specific therapeutic agent. *Medizinische Monatsschrift Fur Pharmazeuten*, *45*(5), 193–194. https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85133542850&origin=inward